Sign in

    Shashank Krishnakumar

    Senior Research Analyst specializing in pharmaceutical equity research at Emkay Global

    Shashank Krishnakumar is a Senior Research Analyst specializing in pharmaceutical equity research at Emkay Global Financial Services, focusing on major companies such as Cipla and Sun Pharma. He regularly participates in high-profile earnings calls, providing in-depth coverage and market insights for India's leading pharma firms, though public sources do not reveal specific performance statistics or TipRanks rankings. Krishnakumar began his current role at Emkay Global in 2024 and is registered under SEBI's Research Analyst Regulations, 2014. His professional background highlights expertise in pharma sector trends, and he is recognized for his sectoral knowledge within India's financial services industry.

    Shashank Krishnakumar's questions to DR REDDYS LABORATORIES (RDY) leadership

    Shashank Krishnakumar's questions to DR REDDYS LABORATORIES (RDY) leadership • Q1 2026

    Question

    Shashank Krishnakumar of Emkay Global Financial Services Ltd asked for the value of the out-licensing income booked in the quarter and questioned how the company could maintain its pace of complex generic launches while moderating R&D spend.

    Answer

    CFO M V Narasimham quantified the out-licensing income at ₹120 crores, noting it's a recurring part of the business. CEO Erez Israeli explained that current R&D spending impacts products 10-12 years in the future, so moderating it now does not affect the launch pipeline for the immediate term, as those products are already developed or filed.

    Ask Fintool Equity Research AI

    Shashank Krishnakumar's questions to DR REDDYS LABORATORIES (RDY) leadership • Q4 2025

    Question

    Shashank Krishnakumar asked if Dr. Reddy's anticipates any meaningful benefit from the import alert issued to a competitor's facility for Revlimid, given the volume restrictions in place.

    Answer

    CEO Erez Israeli stated concisely that he does not believe the competitor's import alert will have any impact on Dr. Reddy's.

    Ask Fintool Equity Research AI